Yang H, et al. - In Taiwan, investigators used proton pump inhibitors (PPIs) to study the risk of chronic kidney disease (CKD) in patients with diabetes. This population-based cohort study is based on a specific diabetic database obtained from the National Health Insurance Research Database. Individuals with a new diagnosis of diabetes were enrolled between 2002 and 2013. Compared with non-exposure users, those in the exposure group of PPIs demonstrated a greater prevalence of anemia, anti-hypertension medication and non-steroid anti-inflammation drug prescriptions. According to the findings, the use of PPIs was correlated with a 1.52-fold increased risk of CKD in diabetic patients when the dosage is over 180 DDD in 1 year.